160 related articles for article (PubMed ID: 30395685)
1. Quantitative Assessment of the Health Risk for Livestock When Animal Viruses Are Applied in Human Oncolytic Therapy: A Case Study for Seneca Valley Virus.
Schijven J; Brizee S; Teunis P; de Vos C; Eblé P; Rutjes S
Risk Anal; 2019 May; 39(5):982-991. PubMed ID: 30395685
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
4. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
[TBL] [Abstract][Full Text] [Related]
5. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone treatment did not exacerbate Seneca Valley virus infection in nursery-age pigs.
Buckley A; Montiel N; Guo B; Kulshreshtha V; van Geelen A; Hoang H; Rademacher C; Yoon KJ; Lager K
BMC Vet Res; 2018 Nov; 14(1):352. PubMed ID: 30453952
[TBL] [Abstract][Full Text] [Related]
7. Non-human viruses developed as therapeutic agent for use in humans.
Koppers-Lalic D; Hoeben RC
Rev Med Virol; 2011 Jul; 21(4):227-39. PubMed ID: 21560181
[TBL] [Abstract][Full Text] [Related]
8. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
Miles LA; Burga LN; Gardner EE; Bostina M; Poirier JT; Rudin CM
J Clin Invest; 2017 Aug; 127(8):2957-2967. PubMed ID: 28650343
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Seneca Valley Virus: past perspectives and future directions.
Burke MJ
Oncolytic Virother; 2016; 5():81-9. PubMed ID: 27660749
[TBL] [Abstract][Full Text] [Related]
10. Pathogenicity of two Chinese Seneca Valley virus (SVV) strains in pigs.
Chen L; Zhang J; Wang M; Pan S; Mou C; Chen Z
Microb Pathog; 2019 Nov; 136():103695. PubMed ID: 31449854
[TBL] [Abstract][Full Text] [Related]
11. Pathogenicity of Seneca Valley virus in pigs and detection in Culicoides from an infected pig farm.
Zhang J; Li C; Meng Y; Xie Y; Shi N; Zhang H; Yu C; Nan F; Xie C; Ha Z; Han J; Li Z; Li Q; Wang P; Gao X; Jin N; Lu H
Virol J; 2021 Oct; 18(1):209. PubMed ID: 34674719
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus.
Jayawardena N; Burga LN; Easingwood RA; Takizawa Y; Wolf M; Bostina M
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10934-E10940. PubMed ID: 30381454
[TBL] [Abstract][Full Text] [Related]
13. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Kennedy EM; Denslow A; Hewett J; Kong L; De Almeida A; Bryant JD; Lee JS; Jacques J; Feau S; Hayes M; McMichael EL; Wambua D; Farkaly T; Rahmeh AA; Herschelman L; Douglas D; Spinale J; Adhikari S; Deterling J; Scott M; Haines BB; Finer MH; Ashburn TT; Quéva C; Lerner L
Nat Commun; 2022 Oct; 13(1):5907. PubMed ID: 36207308
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG
Hum Vaccin Immunother; 2015; 11(7):1573-84. PubMed ID: 25996182
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of a Seneca Valley virus thermostable mutant.
Jayawardena N; McCarthy C; Wang I; Waqqar S; Burga LN; Strauss M; Bostina M
Virology; 2022 Oct; 575():74-82. PubMed ID: 36084546
[TBL] [Abstract][Full Text] [Related]
16. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
[TBL] [Abstract][Full Text] [Related]
17. Regulatory aspects of oncolytic virus products.
Yamaguchi T; Uchida E
Curr Cancer Drug Targets; 2007 Mar; 7(2):203-8. PubMed ID: 17346112
[TBL] [Abstract][Full Text] [Related]
18. Seneca Valley virus induces proinflammatory cytokine and chemokine response
Dong J; Chen M; Yu L; Rao D; Zhang N; Cong F
Can J Vet Res; 2023 Apr; 87(2):120-126. PubMed ID: 37020572
[TBL] [Abstract][Full Text] [Related]
19. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
[TBL] [Abstract][Full Text] [Related]
20. The third wave of Seneca Valley virus outbreaks in pig herds in southern Brazil.
Vieira MV; Yasumitsu CY; Dall Agnol AM; Leme RA; Alfieri AF; Alfieri AA
Braz J Microbiol; 2022 Sep; 53(3):1701-1706. PubMed ID: 35554870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
